Pomdoctor's Four-Tier Model Is Not a Business Plan, It's a Promise

The competitor headline says Pomdoctor has unveiled a four-tier revenue model. The word "unveiled" is the first thing to get wrong about this story. You don't unveil something you haven't built yet. Pomdoctor's four tiers - AI-powered services, healthcare data, professional medical services, and ecosystem partnerships - are described in their own words as under development. That's not an unveiling. That's a wish list filed as a press release.

So the real question isn't whether the model is clever. It's whether Pomdoctor's actual business is good enough to earn the right to try building it.

Let's start with the numbers.

In fiscal year 2025, which ended December 31, 2025, Pomdoctor brought in RMB399.9 million - about US$57 million - a 16.7% increase from the prior year. That growth sounds solid until you look at what drove it. The vast majority came from online pharmacy sales through its internet hospital, which jumped from RMB87.8 million to RMB149.2 million. Consulting services - the thing you'd associate with an actual doctor platform - brought in about RMB1.2 million in fiscal 2024 and increased only slightly in fiscal 2025.

The gross margin for the whole company was 13.1%, down from 13.9% the year before. The internet hospital segment, which you'd expect to be the profitable core, saw its margin drop from 44.7% to 40.5% in the first half of 2025 as lower-margin pharmacy products filled the pipeline. And despite growing revenue, Pomdoctor lost RMB130.9 million - US$18.7 million - a loss that management attributed partly to one-time IPO expenses but was also inflated by a 328.5% increase in R&D spending.

What those numbers tell you is this: Pomdoctor is a thin-margin pharmacy business that happens to sit inside a company talking about becoming an AI-powered healthcare infrastructure provider. The pharmacy growth is real. The margin compression is real. The AI infrastructure is a direction, not a revenue stream.

Management is clear about the ambition. The chairman and CEO, Zhenyang Shi, described the strategy in the company's fiscal 2025 results release as an upgrade centered on "artificial intelligence (AI) + medical-grade smart wearables + full-cycle chronic disease management." A few months later, in July 2026, the company announced it was officially repositioning itself as a foundational infrastructure provider for predictive healthcare data and services. The second July press release leaned on real-world data - the kind of data generated by daily patient interactions, wearables, and remote monitoring - and cited market projections suggesting the global real-world data market could grow from roughly US$2.15 billion in 2026 to about US$7 billion by 2035.

The market size is not the problem. The problem is the distance between a $57 million pharmacy business and the infrastructure company the press releases describe.

I haven't seen evidence that any of the four tiers is yet a functioning product line. The AI-powered services tier doesn't appear in the financial statements. Healthcare data is mentioned as an asset class the company is building toward, but there's no licensing revenue, no data sales, no pricing model. Professional medical services - presumably the doctor consultations - correspond to the consultation line, which brought in about RMB1.2 million in fiscal 2024 and only slightly more in fiscal 2025. Ecosystem partnerships are discussed in principle but aren't itemized in the results.

That's not necessarily a problem. The biggest infrastructure companies started as something else. But it is a problem if investors read a four-tier framework and start pricing in a platform business that hasn't existed.

There's a harder question beneath that one. Pomdoctor's core advantage - it has over 212,000 contracted doctors and about 700,000 transacting patients as of the end of 2024 - is built on scale. That's a real asset. But scale in the pharmacy business is also a race. Any number of Chinese internet platforms can sell medicine online. The margin tells you how defensible that position is. Thirteen percent isn't a moat. It's a pass-through operation with a small markup.

The company's classification as "other medical services" in the healthcare sector captures this ambiguity. It's not a pure pharma distributor. It's not a pure clinic. It's something still figuring out what it is.

AInvest's aggregate signal gives Pomdoctor a fundamental rating of 9.36 out of what appears to be a higher scale, with a liquidity rating of 7.17, but no analyst consensus rating is available. That absence is worth sitting with. It suggests the stock hasn't attracted enough institutional coverage to generate a conventional view, which is normal for a tiny-cap post-IPO name but also means there's no external pressure-testing of the four-tier thesis.

The way to think about Pomdoctor is not as a company with a new revenue model. It's a company that needs to prove its existing model can generate enough cash and data volume to make the new one plausible. The online pharmacy sales grew 69% in the internet hospital segment, which is impressive. But that growth came by deepening partnerships with pharmaceutical manufacturers to sell their products through Pomdoctor's platform. That's a distribution play. Distribution businesses compete on volume and price. They don't compound on intelligence.

The four-tier model could work if the pharmacy business is just the customer-acquisition channel and the real economics come later from data, AI tools, and partnerships. Some companies do that. The risk is that the pharmacy business stays the main business, the margins stay thin, and the infrastructure layer never reaches critical mass because it lacks the cash to build it.

Here's what to watch. The next earnings release should tell you whether online pharmacy continues to outgrow the rest of the business, and whether gross margin stabilizes or compresses further. If the four tiers are real, you should see at least one of them - probably healthcare data or AI services - showing up as a disclosed revenue line, however small. If the next two quarters only show pharmacy growth and continued losses, the framework is marketing, not strategy.

The test isn't whether Pomdoctor can describe a future. The test is whether its current economics leave room to build one.